Breaking News Instant updates and real-time market news.

ESPR

Esperion

$50.63

-0.36 (-0.71%)

, CNCE

Concert Pharmaceuticals

$11.20

0.22 (2.00%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55

JMP securities to hold a conference

Life Sciences Conference will be held in New York on June 19-20.

ESPR

Esperion

$50.63

-0.36 (-0.71%)

CNCE

Concert Pharmaceuticals

$11.20

0.22 (2.00%)

CYTK

Cytokinetics

$11.13

0.11 (1.00%)

MNKD

MannKind

$1.20

-0.01 (-0.83%)

ENTA

Enanta

$90.06

-0.79 (-0.87%)

CLSD

Clearside Biomedical

$1.05

(0.00%)

DBVT

DBV Technologies

$8.42

-0.06 (-0.71%)

SLGL

Sol-Gel Technologies

$9.12

0.24 (2.70%)

KPTI

Karyopharm

$5.94

0.03 (0.51%)

PRQR

ProQR Therapeutics

$10.94

-0.68 (-5.85%)

SYRS

Syros Pharmaceuticals

$6.93

0.06 (0.87%)

HSDT

Helius Medical

$2.85

-0.04 (-1.38%)

NVTR

Nuvectra

$3.80

0.03 (0.80%)

CCXI

ChemoCentryx

$8.57

-0.16 (-1.83%)

PLXP

PLx Pharma

$4.93

(0.00%)

AIMT

Aimmune

$20.10

-0.1 (-0.50%)

HALO

Halozyme

$16.63

0.2 (1.22%)

AERI

Aerie Pharmaceuticals

$32.89

-0.94 (-2.78%)

SIBN

SI-Bone

$18.00

0.32 (1.81%)

BCRX

BioCryst

$3.59

-0.01 (-0.28%)

SSKN

Strata Skin Sciences

$2.56

0.08 (3.23%)

JNCE

Jounce Therapeutics

$4.86

0.02 (0.41%)

  • 20

    Jun

  • 24

    Jun

  • 25

    Jun

  • 06

    Jul

  • 10

    Jul

  • 11

    Jul

  • 31

    Jul

  • 01

    Aug

  • 13

    Sep

  • 19

    Oct

ESPR Esperion
$50.63

-0.36 (-0.71%)

05/06/19
JEFF
05/06/19
NO CHANGE
Target $85
JEFF
Buy
No plans for FDA panel removes Esperion bear case, says Jefferies
Jefferies analyst Michael Yee believes the FDA's communication to Esperion Therapeutic that it does not plan to host an advisory panel removes a bear argument. The analyst is surprised by the news and keeps a Buy rating on the shares with an $85 price target.
05/06/19
FBCO
05/06/19
NO CHANGE
Target $90
FBCO
Outperform
Esperion price target raised to $90 from $79 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Esperion to $90 from $79 as he believes the FDA's decision to accept the BA NDA and not hold an AdCom will be viewed favorably and likely will result in substantial upside as investors price in a higher assumed regulatory PoS. While the FDA could request an AdCom at a later date, the analyst is not aware of an example where an AdCom was requested after a sponsor was told it was not needed at acceptance. Auster reiterates an Outperform rating on the shares.
05/06/19
BOFA
05/06/19
UPGRADE
BOFA
Neutral
Esperion upgraded to Neutral from Underperform at BofA/Merrill
05/29/19
GSCO
05/29/19
DOWNGRADE
Target $50
GSCO
Sell
Esperion downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi downgraded Esperion Therapeutics to Sell from Neutral with an unchanged price target of $50. With the regulatory path for bempedoic acid "looking clear," the analyst downgrades the shares on valuation following the recent outperformance. He sees the launch in 2020 as the next driver of the stock.
CNCE Concert Pharmaceuticals
$11.20

0.22 (2.00%)

06/13/19
06/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delphi Technologies (DLPH) upgraded to Buy from Neutral at Goldman Sachs with analyst David Tamberrino saying new CEO Rick Dauch's more operationally focused initiatives should drive "idiosyncratic" margin and free cash flow expansion into 2020. 2. Williams-Sonoma (WSM) upgraded to Accumulate from Hold at Gordon Haskett with analyst Chuck Grom saying following the meetings, and based on more upbeat than expected results from peer RH (RH), he has a higher degree of confidence about both the company's near-term results and its long-term options. 3. Concert Pharmaceuticals (CNCE) upgraded to Buy from Neutral at Janney Montgomery Scott with analyst Esther Hong saying CTP-692 broadens Concert 's clinical pipeline. 4. CenterPoint Energy (CNP) upgraded to Buy on valuation at BofA/Merrill with analyst Julien Dumoulin-Smith citing "compelling" valuation. 5. HCP (HCP) upgraded to Outperform from Market Perform at Raymond James with analyst Jonathan Hughes citing relative valuation and size, development contributions visibility, and accelerating same-store NOI growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/19
HCWC
06/13/19
NO CHANGE
Target $29
HCWC
Buy
Concert Pharmaceuticals price target raised to $29 from $26 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Concert Pharmaceuticals to $29 from $26 saying the safety data of CTP-692 "cleared a major hurdle." The analyst believes a sizable portion of the development risk for CTP-692 is related to safety and dose in clinical trials. As such, the Phase 1 results reported yesterday "cleared a major roadblock, and significantly de-risked the molecule risk," Fein tells investors in a research note. He reiterates a Buy rating on Concert Pharmaceuticals.
04/09/19
JMPS
04/09/19
NO CHANGE
Target $20
JMPS
Outperform
Concert Pharmaceuticals price target lowered to $20 from $26 at JMP Securities
JMP Securities analyst Liisa Bayko lowered her price target on Concert Pharmaceuticals (CNCE) shares to $20 from $26 after USPTO ruled in favor of Incyte (INCY) that claims in Concert's '149 patent are not patentable. Concert said it will appeal the decision, but Bayko thinks a reversal of the PTAB decision is unlikely. She now assumes only 5.5 years of exclusivity for CTP-543, continues to recommend Concert, stating that she sees a $1B opportunity in alopecia areata given the size, unmet need, and competitive landscape. Bayko keeps an Outperform rating on Concert shares.
06/13/19
JANY
06/13/19
UPGRADE
Target $16
JANY
Buy
Concert Pharmaceuticals upgraded to Buy from Neutral at Janney Montgomery Scott
Janney Montgomery Scott analyst Esther Hong upgraded Concert Pharmaceuticals to Buy from Neutral and raised her price target for the shares to $16 from $14. CTP-692 broadens Concert 's clinical pipeline, Hong tells investors in a research note.
CYTK Cytokinetics
$11.13

0.11 (1.00%)

05/06/19
PIPR
05/06/19
NO CHANGE
Target $14
PIPR
Overweight
Cytokinetics' reldesemtiv appears active despite trial miss, says Piper Jaffray
While Cytokinetics' Phase III data for reldesemtiv missed the primary endpoint of slow vital capacity at 12 weeks, the drug did show benefits over placebo in amyotrophic lateral sclerosis, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. He points out the company intends to advance reldesemtiv into a Phase III ALS trial. The analyst reiterates an Overweight rating on Cytokinetics and boosted his price target for the shares to $14 from $13.
02/20/19
PIPR
02/20/19
NO CHANGE
Target $12
PIPR
Overweight
Piper reiterates Overweight rating on Cytokinetics after Amgen starts study
After Cytokinetics (CYTK) announced that partner Amgen (AMGN) has initiated a Phase 1 study of cardiac troponin activator AMG 594, Piper Jaffray analyst Edward Tenthoff said he envisions the two developing AMG 594 in heart failure with reduced ejection fraction, or HFrEF. The analyst, who noted he awaits the futility analysis of the Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in HFrEF patients, which is expected to be reported in the first half of the year, reiterated an Overweight rating and $12 price target on Cytokinetics shares.
03/20/19
PIPR
03/20/19
NO CHANGE
PIPR
Cytokinetics price target raised to $13 from $12 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Cytokinetics and raised his price target on shares to $13 from $12 after Cytokinetics and its partners announced that omecamtiv mecarbil has passed a futility analysis in the Phase III GALACTIC-HF trial, which will continue enrolling ~8,000 HFrEF patients. The analyst anticipates an interim efficacy analysis in 2020, prior to final data likely in 2021.
05/06/19
HCWC
05/06/19
NO CHANGE
Target $26
HCWC
Buy
Cytokinetics price target raised to $26 from $21 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $26 from $21 and keeps a Buy rating on the shares. While the Phase 2 trial testing reldesemtiv in patients with amyotrophic lateral sclerosis missed its endpoint misses, reldesemtiv activity was "clear and broad,: setting up the next steps, Pantginis tells investors in a research note titled "Bad Headline, Impressive Data; Reldesemtiv Effects Consistent; Target Increased to $26." The analyst believes the data show important characteristics of reldesemtiv, including comparable effects across all doses, consistent effects across all timepoints, and durability of the effects.
MNKD MannKind
$1.20

-0.01 (-0.83%)

05/14/19
BTIG
05/14/19
INITIATION
Target $3
BTIG
Buy
MannKind initiated with a Buy, $3 price target at BTIG
BTIG analyst Robert Hazlett initiated coverage of MannKind with a Buy rating and $3 price target. The stock closed Monday down 2c to $1.23. With the advancements of continuous glucose monitor technologies, tighter glycemic control will become more of a focus, and MannKind's Afrezza "can play a material role," Hazlett tells investors in a research note. The analyst estimates inhaled insulin Afrezza's peak U.S. sales at greater than $350M. Mannkind's recently revamped management is attempting to energize Afrezza through publications of differentiating data, which can improve acceptance among physicians and patients, helping "solid growth continue," according to Hazlett.
03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/19
05/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with a Buy, $3 price target at BTIG. 2. Ross Stores (ROST) and TJX (TJX) initiated with an Outperform at Baird. 3. Elastic (ESTC) initiated with a Hold at Stifel. 4. CytomX Therapeutics (CTMX) initiated with an Overweight at Cantor Fitzgerald. 5. FIS (FIS) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/19
HCWC
05/08/19
NO CHANGE
Target $3
HCWC
Buy
MannKind price target lowered to $3 from $4 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $3 from $4 saying that while Q2 is already shaping up better than Q1, the slower Afrezza ramp drives an estimate reduction. The analyst, however, still believes MannKind's pipeline "is all potential upside" to his model. He keeps a Buy rating on the shares.
ENTA Enanta
$90.06

-0.79 (-0.87%)

12/13/18
12/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) assumed with a Buy at Mizuho. 2. Molson Coors (TAP) and Keurig Dr Pepper (KDP) were initiated with a Buy at UBS, while PepsiCo (PEP) and Constellation Brands (STZ) were initiated with a Neutral, and Monster Beverage (MNST) and Boston Beer (SAM) were initiated with a Sell. 3. SeaSpine (SPNE) initiated with an Outperform at Wells Fargo. 4. XPO Logistics (XPO) initiated with a Buy at SunTrust. 5. Enanta (ENTA) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
JMPS
04/15/19
NO CHANGE
Target $116
JMPS
Outperform
Enanta early data on EDP-514 look promising, says JMP Securities
JMP Securities analyst Liisa Bayko said she was impressed with the preclinical data presented by Enanta (ENTA) at the EASL meeting on its HBV core inhibitor candidate EDP-514. When comparing to other core inhibitors in development, EDP-514 "appears at least as potent as the competition" with the exception of Assembly Biosciences' (ASMB) third-generation capsid inhibitor ABI-H3733, said Bayko, who added that EDP-514 has a superior reduction in HBV viral load than ABI-H3733 and a lower EC50 level than Assembly's first- and second-generation inhibitors. Bayko keeps an Outperform rating and $116 price target on Enanta shares.
05/24/19
WOLF
05/24/19
INITIATION
Target $117
WOLF
Outperform
Enanta initiated with an Outperform at Wolfe Research
Wolfe Research initiated Entana with an Outperform and $117 price target.
04/23/19
BREN
04/23/19
UPGRADE
BREN
Buy
Enanta upgraded to Buy from Hold at Berenberg
CLSD Clearside Biomedical
$1.05

(0.00%)

11/05/18
STFL
11/05/18
DOWNGRADE
Target $4
STFL
Hold
Clearside Biomedical downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy earlier downgraded Clearside Biomedical to Hold from Buy following the failure of the SAPPHIRE trial in RVO and subsequent discontinuation of the program. Clearside's value now depends primarily on the success of Xipere for the treatment of macular edema associated with non-infectious uveitis, said Samimy, who lowered her price target on the stock to $4 from $20. The SAPPHIRE failure also has implications for the future clinical design for DME, since "designing it as a superiority trial appears off the table now," Samimy believes.
11/05/18
JPMS
11/05/18
DOWNGRADE
Target $8
JPMS
Underweight
JPMorgan double downgrades Clearside to Underweight on study failure
JPMorgan analyst Anupam Rama double downgraded Clearside Biomedical to Underweight from Overweight and lowered his price target for the shares to $8 from $16. The stock in early trading is down 56%, or $3.12, to $2.44. The analyst also removed Clearside from his firm's Analyst Focus List. The company this morning announced that the Phase 3 Sapphire results for Xipere plus Eylea in retinal vein occlusion did not meet the primary endpoint of third-line gainers versus Eylea alone, Rama tells investors in a research note. The results are "clearly disappointing," says Rama. The analyst sees no material value creation catalysts on the horizon and believes the overall negative sentiment on shares is unlikely to change until the company is closer to approval/commercialization.
11/06/18
NEED
11/06/18
NO CHANGE
Target $4
NEED
Buy
Clearside Biomedical price target lowered to $4 from $22 at Needham
Needham analyst Serge Belanger lowered his price target on Clearside Biomedical to $4 after its announcement yesterday that the Sapphire Phase 3 study evaluating Xipere in RVO patients did not meet its primary endpoint. The analyst also keeps his Buy rating, stating that while Clearside Biomedical is discontinuing the clinical development of its RVO program, it will remain focused on the Xipere opportunity in uveitis. Belanger adds that the valuation on the shares is now below cash levels and fails to capture the uveitis opportunity with potential peak sales of as high as $150M.
11/05/18
COWN
11/05/18
DOWNGRADE
COWN
Market Perform
Clearside Biomedical downgraded earlier to Market Perform at Cowen
DBVT DBV Technologies
$8.42

-0.06 (-0.71%)

05/20/19
FBCO
05/20/19
INITIATION
Target $30
FBCO
Outperform
Aimmune assumed with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman assumed coverage of Aimmune Therapeutics (AIMT) with an Outperform rating and lowered the price target on the stock to $30 from the firm's prior $36 target, citing his belief that AR101 is likely to be approved to reduce risk from exposure in children and adults with peanut allergy. Aimmune's only competitor in peanut allergy treatment, DBV Therapeutics (DBVT), is at least a year behind in his view, Seigerman tells investors.Target $30.
06/17/19
GSCO
06/17/19
INITIATION
Target $14
GSCO
Buy
DBV Technologies initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.
06/17/19
06/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DBV Technologies (DBVT) initiated with a Buy at Goldman Sachs. 2. Amicus (FOLD) initiated with a Buy at H.C. Wainwright. 3. Viper Energy (VNOM) initiated with a Buy at SunTrust. 4. GNC Holdings (GNC) initiated with a Hold at Jefferies. 5. Eventbrite (EB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
STFL
04/10/19
NO CHANGE
STFL
Hold
ICER draft report presents modest headwind for DBV, Aimmune, says Stifel
Stifel analyst Derek Archila noted that ICER, an independent and non-partisan research organization that analyzes the benefits along with costs of treatments, issued a draft report assessing the value and effectiveness of Aimmune's (AIMT) AR101 and DBV Technologies' (DBVT) Viaskin peanut for peanut allergy. He believes ICER's cost-effectiveness analysis re-affirms his cautious approach on the peanut immunotherapy category and believes the report presents a modest headwind for the stocks. However, this was only a draft report in which ICER made assumptions for costs since no official pricing has been announced for either therapy, Archlia noted. He maintains Hold ratings on both Aimmune and DBV Technologies.
SLGL Sol-Gel Technologies
$9.12

0.24 (2.70%)

07/16/18
HCWC
07/16/18
INITIATION
Target $21
HCWC
Buy
Sol-Gel Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Sol-Gel Technologies with a Buy rating and $21 price target. The analyst believes peak Twin sales may approach $260M by 2028 while while Vered might reach peak sales of $785M in 2027.
KPTI Karyopharm
$5.94

0.03 (0.51%)

03/15/19
WEDB
03/15/19
NO CHANGE
WEDB
Wedbush views Karyopharm 's PDUFA date extension as a positive
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
03/01/19
JPMS
03/01/19
DOWNGRADE
Target $7
JPMS
Neutral
Karyopharm downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Karyopharm Therapeutics to Neutral and lowered his price target for the shares to $7 from $21. The analyst sees a "rocky regulatory road" forward for the company.
06/14/19
HCWC
06/14/19
NO CHANGE
Target $29
HCWC
Buy
Karyopharm EHA Phase 1b/2 combination data 'encouraging,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $29 price target on Karyopharm, saying the company presented "encouraging" early Phase 1b/2 selinexor combination data from the STOMP trial in relapsed or refractory multiple myeloma patients at the European Hematological Association 2019 Annual Meeting. In a research note to investors, White says the updated selinexor with Darzalex data "continues to look good," with efficacy results showing an overall response rate of 73% in Darzalex naive patients versus the EHA abstract data published last month with an ORR of 77%. Looking ahead, White projects revenues of $189M and $241M for selinexor in penta-refractory multiple myeloma and DLBCL, respectively, in 2026. For selinexor in combination multiple myeloma treatment, he forecasts revenues of $332M in 2026, and for selinexor in solid tumors he sees revenues of $241M in 2026.
02/28/19
HCWC
02/28/19
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright says selinexor expectations not changed by ODAC recommendation
After the FDA's Oncologic Drugs Advisory Committee, or ODAC, voted on February 26 to recommend that the FDA wait for the Phase 3 BOSTON trial results before deciding on selinexor's NDA application, H.C. Wainwright analyst Edward White noted that the decision was not unanimous and said "the FDA typically but does not always follow the ODAC panel's recommendations." It is possible that a delay to wait for the BOSTON data could push out a selinexor launch by one year or more, but the ODAC recommendation is "not changing our expectations," stated White, who keeps a Buy rating and $30 price target on shares of Karyopharm.
PRQR ProQR Therapeutics
$10.94

-0.68 (-5.85%)

02/20/19
SBSH
02/20/19
NO CHANGE
SBSH
Buy
Citi opens 90-day catalyst watch on ProQR Therapeutics
Citi analyst Yigal Nochomovitz opened a 90-day catalyst watch on ProQR Therapeutics in anticipation of the interim Phase 1/2 Wings data for QR-313 in dystrophic epidermolysis bullosa. On positive data, or evidence of exon skipping in biopsies and evidence of skin lesion/blister resolution, the analyst sees the stock up 15%-25%. On negative data, he sees downside of 10%-15%. Nochomovitz has a Buy rating on ProQR Therapeutics.
01/14/19
CANT
01/14/19
NO CHANGE
CANT
Cantor highlights BioMarin, ProQR after JPMorgan Healthcare Conference
Cantor Fitzgerald analyst Eliana Merle found BioMarin's (BMRN) gene therapy platform advances and "improved risk-reward" for ProQR Therapeutics' (PRQR) USH2A program ahead of key data mid-2019 as most notable from the JPMorgan Healthcare Conference. The analyst left feeling more confident about BioMarin's gene therapy platform, which she thinks could positively surprise over the next 12-24 months as new programs enter the clinic. Further, she thinks the safety events in question at this point are likely overdone in ProQR shares following the 15% selloff since the conference. Merle now sees an "even more" favorable risk/reward into the company's mid-2019 proof-of-concept readout from a separate program.
03/27/19
CANT
03/27/19
NO CHANGE
Target $40
CANT
Overweight
ProQR Therapeutics spin-out 'smart, but not surprising,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle thinks ProQR Therapeutics' spin-out of its dystrophic epidermolysis bullosa program is a "smart, but not surprising," strategic move. Given that the company has communicated it wants to focus on its ophthalmology programs, investors are unlikely to find this announcement about the skin program spin-out surprising, Merle tells investors in a research note. The analyst keeps an Overweight rating on ProQR Therapeutics with a $40 price target.
12/19/18
RBCM
12/19/18
INITIATION
Target $29
RBCM
Outperform
ProQR Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated ProQR Therapeutics with an Outperform rating and a price $29. The analyst believes that the company's recent QR-110 data serves to de-risk its ophthalmology portfolio, offering "upside potential from pipeline expansion in 2019" and beyond. MacKay is also positive on ProQR Therapeutics position of having an "established proof of concept utilizing RNA-based therapies to target rare diseases uniquely sheltered from safety and efficacy challenges" faced by its therapeutic class.
SYRS Syros Pharmaceuticals
$6.93

0.06 (0.87%)

03/08/19
JMPS
03/08/19
INITIATION
Target $18
JMPS
Outperform
Syros Pharmaceuticals initiated with an Outperform at JMP Securities
JMP Securities transferred coverage of Syros Pharmaceuticals to analyst Jason Butler, who established an Outperform rating and $18 price target on the stock. He believes the company's recently updated clinical development strategies can provide faster paths to market and maximize commercial potential for SY-1425 and SY-1365, Butler tells investors.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
PIPR
04/10/19
NO CHANGE
Target $24
PIPR
Overweight
Syros Pharmaceuticals price target lowered to $24 from $28 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Syros Pharmaceuticals to $24 from $28 to account for dilution of the company's recent $70M capital raise. The analyst, however, reiterates an Overweight rating on the name. Syros is developing potentially best-in-class CDK7 inhibitors, Tenthoff tells investors in a research note. He points out that data from the expansion cohorts in ovarian cancer are expected in Q4.
02/14/19
OPCO
02/14/19
INITIATION
Target $13
OPCO
Outperform
Syros Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach assumed coverage of Syros Pharmaceuticals with an Outperform rating and a $13 price target. The analyst believes the company's lead program, SY-1425, has demonstrated compelling clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates, he contends. Nonetheless, Breidenbach sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.
HSDT Helius Medical
$2.85

-0.04 (-1.38%)

04/11/19
04/11/19
DOWNGRADE

Perform
Helius Medical downgraded to Perform on FDA PoNS update at Oppenheimer
As previously reported, Oppenheimer analyst Steven Lichtman downgraded Helius Medical to Perform from Outperform following the update on the FDA submission for the company's PoNS, with the agency declining approval and more data needed for resubmission. The next key milestones include the update on U.S. pathway following another expected FDA meeting and potential approvals in Europe/Australia, he contends.
04/11/19
OPCO
04/11/19
DOWNGRADE
OPCO
Perform
Helius Medical downgraded to Perform from Outperform at Oppenheimer
04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Helius Medical downgraded to Neutral from Buy at BTIG
04/16/19
BTIG
04/16/19
DOWNGRADE
BTIG
Neutral
Helius Medical downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Helius Medical to Neutral following last week's FDA announcement denying the company the request for de novo classification and 510(k) clearance for its Portable Neuromodulation Stimulator, or PoNS device. The analyst notes that there was some risk around the decision, but sees the decision as surprising since he believes that contrary to the FDA thinking, the company's submission "did separate" the impacts of the device and physical therapy toward symptom improvements. Lavin contends that Helius Medical may now have to conduct a new prospective trial which would require a "good deal of time and capital", adding that "significant dilution may be necessary."
NVTR Nuvectra
$3.80

0.03 (0.80%)

04/11/19
PIPR
04/11/19
NO CHANGE
PIPR
Piper sees Nuvectra, Boston Scientific as winners in spinal cord stimulation
After surveying 37 clinicians on the present and future treatment of low back pain, Piper Jaffray analyst Matt O'Brien believes the spinal cord stimulation market is poised to continue "growing quickly." While the survey indicated Nevro (NVRO) and Nuvectra (NVTR) would pick up market share this year, O'Brien believes Boston Scientific (BSX) and Nuvectra will be the "primary share-gainers."
05/02/19
PIPR
05/02/19
NO CHANGE
Target $18
PIPR
Overweight
Nuvectra selloff brings attractive entry point, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is not overly surprised by the pushed out Virtis approval timeline and believes Nuvectra shares largely reflected the likelihood given how long it took to hear back from the FDA. On the positive side, the company's spinal cord stimulation momentum continues to demonstrate above market growth, which will be supported by salesforce expansion and a key MR full-body approval by Q4, O'Brien tells investors in a post-earnings research note. He believes today's selloff represents an attractive entry point for investors and keeps an Overweight rating on Nuvectra. O'Brien lowered his price target for the shares to $18 from $20.
05/02/19
JMPS
05/02/19
NO CHANGE
Target $18
JMPS
Outperform
Nuvectra price target lowered to $18 from $26 at JMP Securities
JMP Securities analyst David Turkaly noted a few negative takeaways from Nuvectra's Q1 earnings call, foremost among them being news that the FDA has requested additional information as part of the pending PMA application for approval of its Virtis sacral nerve stimulation product and will collect supplementary data on the biocompatibility of the device's leads. While he believes Nuvectra shares are already trading at a depressed valuation and keeps an Outperform rating on the stock, Turkaly lowered his price target on shares to $18 to reflect the extended timeline on Virtis and his lowered 2020 sales estimate.
05/16/19
PIPR
05/16/19
NO CHANGE
PIPR
Overweight
Piper defends shares of Nuvectra after another executive leaves
Piper Jaffray analyst Matt O'Brien says he's continuing to defend shares of Nuvectra after another executive departed, this time COO and CFO Walter Berger. CEO transitions, like the one that just occurred at the company, are usually followed by additional executive departures, O'Brien tells investors in a research note. He does not believe the timing of Berger's departure and the recently amended Virtis timing are related. The analyst continues to believe Nuvectra has a strong spinal cord stimulation franchise and will eventually obtain approval for Virtis. O'Brien thinks risk-tolerant investors to take a look at the name here and he reiterates an Overweight rating on Nuvectra shares.
CCXI ChemoCentryx
$8.57

-0.16 (-1.83%)

06/06/19
ADAM
06/06/19
NO CHANGE
Target $14
ADAM
Buy
ChemoCentryx price target lowered to $14 from $20 at Canaccord
Canaccord analyst Michelle Gilson lowered her price target on ChemoCentryx to $14 from $20 following the failure of IFX-1 failing to validate the C5a hypothesis in HS. The analyst believes AAV (associated vasculitis) remains a better indication than HS and is central to his buy thesis. Gilson maintained her Buy rating on ChemoCentryx shares.
06/05/19
06/05/19
DOWNGRADE

Market Perform
InflaRx downgraded to Market Perform on HS study results at Raymond James
As previously reported, Raymond James analyst Steven Seedhouse downgraded InflaRx (IFRX) to Market Perform from Outperform as it is now trading below cash and thereby baking in what he believes is an appropriate value, which is zero value for hidradenitis suppurativa and risk to all follow-on indications in the pipeline for IFX-1. The analyst acknowledges that HS may not be a viable indication for C5a pathway inhibition, which seems "quite clear from InflaRx's failed study." Seedhouse adds that there is "obvious negative read-through" to Chemocyntrx (CCXI), which is running a large Phase 2 randomized study in HS for avacopan. He expects that study to at a minimum fail or maybe even be stopped early given the complete lack of signal demonstrated by IFX-1.
06/05/19
PIPR
06/05/19
NO CHANGE
Target $17
PIPR
Overweight
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
Piper Jaffray analyst Edward Tenthoff lowered his price target for ChemoCentryx (CCRX) to $17 from $20 after its competitor InflaRx (IFRX) reported negative Phase IIb data for C5a antibody IFX-1 to treat moderate-to-severe hidradenitis suppurativa. ChemoCentryx shares are down because the company has its own small molecule avacopan targeting C5a receptor in an ongoing Phase II hidradenitis suppurativa study with data in 2020, Tenthoff tells investors in a research note. The analyst says that while nuances exist between InflaRx's IFX-1 and ChemoCentryx's avocopan for receptor coverage and distribution, the lack of dose response in InflaRx's Phase II data raises concern over the relevancy of C5a in hidradenitis suppurativa. As a result, Tenthoff removed value for avacopan in hidradenitis suppurativa in his model but remains a buyer of ChemoCentryx shares for the Phase III Advocate avacopan data in ANCA-associated vasculitis in Q4 of this year. He keeps an Overweight rating on the shares, which are down 17% to $9.18 in afternoon trading.
06/06/19
RAJA
06/06/19
NO CHANGE
Target $17
RAJA
Strong Buy
ChemoCentryx price target lowered to $17 from $24 at Raymond James
Raymond James analyst Steven Seedhouse removed hidradenitis suppurativa from his model for ChemoCentryx (CCXI) after InflaRx (IFRX) reported that its Phase IIb trial for C5a antibody IFX-1 failed, leading him to lower his price target on the shares to $17 from $24. However, he keeps a Strong Buy rating on ChemoCentryx shares and said he would be a buyer amid the weakness, citing Phase 2 data for avacopan in AAV and a near-term Phase 3 data readout for AAV in Q4.
PLXP PLx Pharma
$4.93

(0.00%)

03/14/19
JMPS
03/14/19
INITIATION
Target $15
JMPS
Outperform
PLx Pharma initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis initiated PLX Pharma with an Outperform rating and $15 price target, noting that the company's improved formulation of OTC aspirin provides statistically significant superior antiplatelet activity compared to enteric-coated aspirin and lower GI ulcer and bleeding compared to immediate-release aspirin.
04/12/19
JANY
04/12/19
INITIATION
Target $13
JANY
Buy
PLx Pharma assumed with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Esther Hong assumed coverage of PLx Pharma with a Buy rating and $13 fair value estimate.
03/14/19
03/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Cowen. 2. Fluidigm (FLDM) initiated with a Buy at BTIG. 3. Kala Pharmaceuticals (KALA) initiated with a Buy at Jefferies. 4. PLx Pharma (PLXP) initiated with an Outperform at JMP Securities. 5. Walker & Dunlop (WD) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/14/19
RAJA
01/14/19
DOWNGRADE
RAJA
Market Perform
PLx Pharma downgraded to Market Perform from Outperform at Raymond James
AIMT Aimmune
$20.10

-0.1 (-0.50%)

06/10/19
CANT
06/10/19
NO CHANGE
Target $45
CANT
Overweight
Cantor has increased conviction in approvability of Aimmune's AR101
After hosting management for investor meetings in Europe and the as well the recent data presentations, Cantor Fitzgerald analyst Charles Duncan has increased conviction about the approvability of Aimmune Therapeutics' AR101 in peanut allergy. The analyst believes the "clear benefit/risk of the candidate" will fuel a "paradigm shift" in the treatment of peanut allergy for, "at least, the highest burden patient cohort" as early as Q4 of 2019. He reiterates an Overweight rating on Aimmune shares with a $45 price target.
06/04/19
JMPS
06/04/19
NO CHANGE
Target $40
JMPS
Outperform
Aimmune data firm up AR101 efficacy profile, says JMP Securities
JMP Securities analyst Liisa Bayko said data from the Phase 3 ARTEMIS study of AR101 for peanut allergy appear consistent with the Phase 3 PALISADE study, even at an earlier time point, and firm up the drug's efficacy profile. Meanwhile, safety looks "slightly better" in ARTEMIS, but this may be due to a shorter trial or differences in the patient population, Bayko added. She thinks the data support an expected MAA submission in mid-2019 and Bayko keeps an Outperform rating on Aimmune shares with a $40 price target.
06/19/19
PIPR
06/19/19
NO CHANGE
Target $60
PIPR
Overweight
Piper views setup for Aimmune shares as 'decidedly positive'
Following a dinner with management which included a review of the Phase 3 Artemis data, Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics with a $60 price target. The key takeaway from the event was the continued execution by management to successfully position AR101 for approval, Raymond tells investors in a research note. The analyst continues to see the setup on Aimmune as "decidedly positive" and he remains a buyer of the stock.
HALO Halozyme
$16.63

0.2 (1.22%)

02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
11/27/18
JEFF
11/27/18
NO CHANGE
Target $9
JEFF
Underperform
Jefferies still sees low likelihood of success for Halozyme's PEGPH20
Following the announced change in the Phase 3 endpoint, Jefferies analyst Eun Yang continues to view probability for success of Halozyme Therapeutics's PEGPH20 in pancreatic cancer as low. The change in the HALO-301 endpoint/data analysis "dampens our confidence further," Yang tells investors in a research note. HALO-301 is a phase 3 global, randomized, double-blind placebo controlled clinical trial evaluating investigational new drug PEGPH20 as a first-line therapy for potential treatment of patients with metastatic pancreas cancer. The analyst remains cautious on Halozyme shares with an Underpeform rating and $9 price target.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
AERI Aerie Pharmaceuticals
$32.89

-0.94 (-2.78%)

06/11/19
CANT
06/11/19
NO CHANGE
Target $85
CANT
Overweight
Aerie drugs transforming glaucoma treatment space, says Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros says that with a year's worth of scripts reported for Rhopressa and an early first month look at the Rocklatan launch, he remains confident that Aerie Pharmaceuticals' two drugs are transforming the glaucoma treatment space. With "superior efficacy established" over the number-one prescribed prostaglandin, Aerie's portfolio of glaucoma treatments is best in class, Piros tells investors in a research note. He reiterates an Overweight rating on the shares with an $85 price target.
06/11/19
ADAM
06/11/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals Q2 script numbers too high, says Canaccord
Canaccord analyst Dewey Steadman said Aerie Pharmaceuticals' Rhopressa and Rocklatan prescriptions were likely impacted by the Memorial Day holiday. As a result, the analyst does not believe the prescription run rate can meet his/consensus revenue expectations for the quarter and that estimates will likely need to come down ahead of its Q2 results. Steadman maintained his Buy rating and $56 price target on Aerie Pharmaceuticals shares.
05/09/19
STFL
05/09/19
NO CHANGE
STFL
Buy
Novartis deal makes Aerie 'look like a steal' at current levels, says Stifel
Stifel analyst Annabel Samimy said Novartis' (NVS) agreement to buy Takeda's (TAK) dry eye product Xiidra for $3.4B upfront in cash and up to an additional $1.9B in potential milestone payments "clearly frames the value for innovative ophthalmologic assets" and makes shares of Aerie Pharmaceuticals (AERI) "look like a steal." Applying the same peak sales multiple that Novartis paid for Xiidra implies a market-value of greater than $6B for Aerie, said Samimy, who noted that she does not expect an immediate takeout of Aerie but remains a buyer of the shares.
05/10/19
ADAM
05/10/19
NO CHANGE
Target $56
ADAM
Buy
Aerie Pharmaceuticals price target cut to $56 from $65 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target for Aerie Pharmaceuticals to $56 from $65 following the company's Q1 results, saying Aerie posted a sequential revenue decline from Q4 and a top- line miss relative to consensus expectations as growth from Rhopressa meaningfully slowed from its post-launch ramp last year. In a research note to investors, Steadman says he thinks Aerie will be highly dependent on a return to Rhopressa growth coupled with exceptionally strong Rocklatan launch metrics to meet its $110M-$120M 2019 revenue guide after posting only ~$11M in Q1 revenue. Steadman "reluctantly" maintains a Buy rating, saying the need to flawlessly execute, coupled with a lack of binary pipeline catalysts, leave him to believe that Aerie shares will likely be rangebound for the near future.
SIBN SI-Bone
$18.00

0.32 (1.81%)

11/12/18
11/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Denali Therapeutics (DNLI) initiated with a Buy at Janney Montgomery Scott. 2. PhaseBio (PHAS) initiated with a Buy at Stifel and Citi as well as an Outperform at Cowen. 3. Osmotica Pharmaceuticals (OSMT) initiated with a Buy at Jefferies as well as an Outperform at Wells Fargo and RBC Capital. 4. SI-Bone (SIBN) initiated with an Outperform at JMP Securities, an Overweight at Morgan Stanley, as well as a Buy at Canaccord and BofA/Merrill. 5. Studio City (MSC) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/18
BOFA
11/12/18
INITIATION
Target $23
BOFA
Buy
SI-Bone initiated with a Buy at BofA/Merrill
BofA Merrill Lynch analyst Bob Hopkins initiated SI-Bone with a Buy rating and $23 price target, stating that he believes the company has the tools, the clinical data, payor coverage and capital to develop iFuse as the standard of care for treating sacroiliac, or SI, joint pain.
11/12/18
MSCO
11/12/18
INITIATION
Target $24
MSCO
Overweight
SI-Bone initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lewis started SI-Bone with an Overweight rating and $24 price target, stating that SI joint fusion could be the "next major orthopedic joint procedure" and that the company's clinically differentiated implant, iFuse, is uniquely positioned to penetrate this significantly underserved market. He also contends the company's unique model is more scalable and profitable than peers, Lewis tells investors.
11/12/18
ADAM
11/12/18
INITIATION
Target $25
ADAM
Buy
SI-Bone initiated with a Buy at Canaccord
Canaccord analyst Kyle rose initiated SI-Bone with a Buy rating as he believes it has the potential to be a classic small-cap me-tech execution story underpinned by an established technology, large addressable market, exceptional gross margin profile and best-in-class clinical data. Rose has a $25 price target on SI-Bone shares.
BCRX BioCryst
$3.59

-0.01 (-0.28%)

05/23/19
JMPS
05/23/19
NO CHANGE
Target $10
JMPS
Outperform
BioCryst price target lowered to $10 from $18 at JMP Securities
JMP Securities analyst Liisa Bayko maintains an Outperform rating on BioCryst Pharmaceuticals after her talks with two key opinion leader doctors supported her view that HAE patients will want to try an oral option and BCX7353 could be "good enough" for a substantial proportion of them. However, she cut her price target on the shares to $10 from $18 to account for the fact that she lowered her U.S. launch price estimate to $250,000 from $500,000 annually.
05/24/19
RBCM
05/24/19
DOWNGRADE
Target $4.5
RBCM
Sector Perform
BioCryst downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Brian Abrahams downgraded BioCryst Pharmaceuticals to Sector Perform from Outperform and lowered his price target for the shares to $4.50 from $16.
05/22/19
JEFF
05/22/19
NO CHANGE
Target $8
JEFF
Buy
BioCryst price target lowered to $8 from $13 at Jefferies
Jefferies analyst Maury Raycroft lowered his price target for BioCryst Pharmaceuticals to $8 from $13 while keeping a Buy rating on the shares. The analyst still believes BCX7353 gets approved and used in the prophy setting, but he admits that use may be more limited with more reliance on pricing strategies following yesterday's Phase 3 data.
05/24/19
05/24/19
DOWNGRADE
Target $4.5

Sector Perform
BioCryst downgraded to Sector Perform at RBC Capital on disappointing '7353 data
As previously reported, RBC Capital analyst Brian Abrahams downgraded BioCryst to Sector Perform from Outperform and lowered his price target to $4.50 from $16. The analyst cites the "disappointing" efficacy data for BCX7353, relegating the drug's potential to a "smaller niche role" even with discount pricing. Abrahams adds that although approvability risks for '7353 may be unfounded and the stock may bounce, he believes that the Street will have to turn more confident about its future revenues to offset the investments in filing and commercialization.
SSKN Strata Skin Sciences
$2.56

0.08 (3.23%)

12/10/18
NORL
12/10/18
INITIATION
Target $7
NORL
Outperform
Strata Skin Sciences initiated with an Outperform at Northland
Northland analyst Suraj Kalia initiated Strata Skin Sciences with an Outperform and $7 price target saying he is encouraged by the new CEO and the recent entry of a VC with a track record of turnarounds.
10/02/18
HCWC
10/02/18
NO CHANGE
Target $5
HCWC
Buy
Strata Skin Sciences price target raised to $5 from $3 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Strata Skin Sciences to $5 after the company announced the completion of a multicenter clinical study investigating efficiency and efficacy of its FDA cleared Multi-Micro Dose diagnostic tip accessory for the company's proprietary XTRAC 308nm excimer laser. These results represent a further improvement from previous studies where XTRAC treatment had shown to achieve PASI-75 clearance in two to four weekly treatments, at higher doses, and in an average of 6.2 treatments, at lower doses, Pantginis tells investors in a research note. He anticipates a "meaningful business impact from OTD data" and keeps a Buy rating on the shares.
09/04/18
DAWS
09/04/18
INITIATION
Target $5
DAWS
Buy
Strata Skin Sciences initiated with a Buy at Dawson James
Dawson James initiated Strata Skin Sciences with a Buy and $5 price target.
JNCE Jounce Therapeutics
$4.86

0.02 (0.41%)

08/13/18
HCWC
08/13/18
NO CHANGE
Target $13
HCWC
Buy
Jounce Therapeutics price target lowered to $13 from $19 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $13 but keeps a Buy rating on the shares. The analyst sees limited near-term catalysts to drive investor sentiment, and he believes there remains "substantial clinical questions that need to be addressed before ICOS agonism comes back to the fore."
06/28/18
RAJA
06/28/18
INITIATION
Target $13
RAJA
Outperform
Jounce Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated Jounce Therapeutics with an Outperform and $13 price target.
11/13/18
JPMS
11/13/18
DOWNGRADE
JPMS
Underweight
Jounce Therapeutics downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov downgraded Jounce Therapeutics to Underweight from Neutral.
11/14/18
JPMS
11/14/18
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Jounce to Underweight on lack of catalysts
JPMorgan analyst Cory Kasimov last night downgraded Jounce Therapeutics to Underweight from Neutral without a price target. It may take the company some time to generate substantial enough clinical data to prompt investors to reengage, Kasimov tells investors in a research note following the company's Q3 results. While the company is well capitalized and has a compelling approach to drug development, Jounce shares could continue to be a relative underperformer given a lack of meaningful clinical catalysts, says the analyst.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,815.98

-7.21 (-0.40%)

14:00
08/22/19
08/22
14:00
08/22/19
14:00
Periodicals
Amazon acquires 49% interest in India's Future Coupons, TechCrunch reports »

Amazon has acquired a 49%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BTHE

Boston Therapeutics

$0.00

(0.00%)

13:56
08/22/19
08/22
13:56
08/22/19
13:56
Hot Stocks
Boston Therapeutics BTI320 Phase 2 study achieves full enrollment »

Boston Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$212.87

0.18 (0.08%)

, BABA

Alibaba

$171.93

-3.26 (-1.86%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Periodicals
EU targets Apple, Google, others with EUR100B wealth fund plan, Politico says »

EU officials want to set…

AAPL

Apple

$212.87

0.18 (0.08%)

BABA

Alibaba

$171.93

-3.26 (-1.86%)

GOOG

Alphabet

$1,191.36

0.57 (0.05%)

GOOGL

Alphabet Class A

$1,192.66

2.4 (0.20%)

AMZN

Amazon.com

$1,815.25

-7.94 (-0.44%)

FB

Facebook

$182.08

-1.48 (-0.81%)

MSFT

Microsoft

$137.45

-1.32 (-0.95%)

BIDU

Baidu

$105.36

-2.55 (-2.36%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 04

    Sep

  • 04

    Sep

  • 06

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

SEDG

SolarEdge

$80.94

-6.93 (-7.89%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Options
SolarEdge put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

13:44
08/22/19
08/22
13:44
08/22/19
13:44
Periodicals
BNP Paribas cutting 500 jobs at securities services arm in France, Reuters says »

BNP Paribas will cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETR

Entergy

$111.35

-0.32 (-0.29%)

13:39
08/22/19
08/22
13:39
08/22/19
13:39
Syndicate
Breaking Syndicate news story on Entergy »

Entergy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

TELL

Tellurian

$9.04

0.75 (9.05%)

13:25
08/22/19
08/22
13:25
08/22/19
13:25
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/22/19
08/22
13:25
08/22/19
13:25
General news
Treasury's $7 B 30-year TIPS reopening was well received »

Treasury's $7 B…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Total Amount data reported »

30-Yr TIPS Auction Total…

NTRA

Natera

$30.66

0.25 (0.82%)

13:18
08/22/19
08/22
13:18
08/22/19
13:18
Hot Stocks
Natera reports 'positive' local coverage determination issued by Palmetto MolDX »

Natera announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/22/19
08/22
13:17
08/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/22/19
08/22
13:16
08/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/22/19
08/22
13:15
08/22/19
13:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NTRA

Natera

$30.53

0.12 (0.39%)

13:13
08/22/19
08/22
13:13
08/22/19
13:13
Recommendations
Natera analyst commentary at Piper Jaffray »

Piper says Natera gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

13:10
08/22/19
08/22
13:10
08/22/19
13:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD peaked…

AMGN

Amgen

$204.16

0.32 (0.16%)

13:06
08/22/19
08/22
13:06
08/22/19
13:06
Hot Stocks
Amgen granted orphan designation for multiple myeloma treatment »

Amgen was granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

ZIOP

Ziopharm

$5.09

-0.06 (-1.17%)

13:05
08/22/19
08/22
13:05
08/22/19
13:05
Options
Ziopharm call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

SNY

Sanofi

$42.69

-0.48 (-1.11%)

13:04
08/22/19
08/22
13:04
08/22/19
13:04
Hot Stocks
Sanofi treatment of systemic sclerosis granted orphan designation »

Sanofi U.S. Service was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 02

    Oct

WFC

Wells Fargo

$45.62

0.63 (1.40%)

13:03
08/22/19
08/22
13:03
08/22/19
13:03
Periodicals
Wells Fargo to pay $6.5M to Navajo Nation to settle account suit, Reuters says »

Wells Fargo intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

ILMN

Illumina

$288.00

-2.5 (-0.86%)

13:02
08/22/19
08/22
13:02
08/22/19
13:02
Hot Stocks
Illumina granted orphan designation neuroblastoma management diagnostic »

Illumina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

OSTK

Overstock.com

$21.84

2.34 (12.00%)

12:49
08/22/19
08/22
12:49
08/22/19
12:49
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$21.40

1.9 (9.74%)

12:45
08/22/19
08/22
12:45
08/22/19
12:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.13

-0.71 (-0.35%)

, ALXN

Alexion

$118.04

3.17 (2.76%)

12:43
08/22/19
08/22
12:43
08/22/19
12:43
Recommendations
Amgen, Alexion analyst commentary at Piper Jaffray »

Piper Jaffray says Amgen…

AMGN

Amgen

$203.13

-0.71 (-0.35%)

ALXN

Alexion

$118.04

3.17 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

12:40
08/22/19
08/22
12:40
08/22/19
12:40
General news
Fed funds futures are lower after the hawkish comments »

Fed funds futures are…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.